Background: Cytosine arabinoside (CA) and prednisolone are drugs commonly used together in the management of canine non-infectious meningoencephalitis (NIME). The aim of this study was to report the haematological findings before and after CA and prednisolone treatment and identify any adverse haematological events in this clinical setting, following the veterinary cooperative oncology group established common terminology criteria for recording adverse events following administration of chemotherapy or biological antineoplastic therapy.
Results: While 48 patients with a presumptive diagnosis of NIME had pretreatment haematology results, only 12 patients met the inclusion criteria of also having post-treatment haematology results available for review after being treated with prednisolone and CA at a standard dose (200 mg/m) in a single referral hospital in the UK. Forty-nine post-treatment haematology results were available for these 12 patients.
Conclusions: Four adverse haematological events were identified in four patients. None of these events were convincingly attributable to CA administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446212 | PMC |
| http://dx.doi.org/10.1136/vetreco-2018-000315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring brain perfusion in dogs with meningoencephalitis of unknown origin: A promising role for arterial spin labeling imaging.
J Vet Intern Med
December 2024
Unit of Diagnostic Imaging, Centre Hospitalier Vétérinaire ADVETIA, Vélizy-Villacoublay, France.
Background: Arterial spin labeling (ASL) is a noninvasive brain perfusion magnetic resonance imaging (MRI) technique that has not been assessed in dogs with meningoencephalitis of unknown origin (MUO).
Hypothesis/objectives: Assess brain perfusion changes characteristics before and after medical treatment, and investigate the role of ASL perfusion in the diagnosis and prognosis of MUO in dogs.
Animals: Thirty-one dogs with presumed MUO.
Of potential new treatment targets and polythetic approach in meningoencephalitis of unknown origin: a review.
Front Vet Sci
October 2024
Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Meningoencephalitis of unknown origin (MUO) represents an umbrella term for inflammatory, non-infectious central nervous system (CNS) diseases in dogs. Current therapeutic approaches, involving long-term glucocorticosteroid use, often fail to provide adequate relief or cure, and the effectiveness of additional immunosuppressive medications remains uncertain. Future advancements in MUO treatment may benefit from patient-specific therapies, potentially enhancing treatment precision, efficacy, and minimizing side effects.
View Article and Find Full Text PDFOn the utility of cerebrospinal fluid biomarkers in canine neurological disorders.
Sci Rep
October 2024
Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravská Cesta 9, Bratislava, Slovak Republic.
Article Synopsis
- The study investigated whether certain cerebral biomarkers (NfL, amyloid-β, tau, NSE) can help diagnose common canine neurological diseases.
- Elevated levels of tau, NfL, and NSE were found in dogs with meningoencephalitis (MUO), while dogs with brain tumors showed an increase in tau and NSE but a decrease in amyloid-β.
- No significant changes in these biomarkers were found in dogs with non-infectious myelopathies, suggesting that NfL, tau, and NSE might be valuable indicators for MUO and brain tumors in dogs.
Viral meningoencephalitis in pediatric solid organ or hematopoietic cell transplant recipients: a diagnostic and therapeutic approach.
Front Pediatr
February 2024
Host Defense Program, Section of Infectious Diseases, Nationwide Children's Hospital, Columbus, OH, United States.
Neurologic complications, both infectious and non-infectious, are frequent among hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients. Up to 46% of HCT and 50% of SOT recipients experience a neurological complication, including cerebrovascular accidents, drug toxicities, as well as infections. Defects in innate, adaptive, and humoral immune function among transplant recipients predispose to opportunistic infections, including central nervous system (CNS) disease.
View Article and Find Full Text PDFRetrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).
BMC Vet Res
December 2023
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 00826, Republic of Korea.
Article Synopsis
- Meningoencephalomyelitis of unknown etiology (MUE) is a non-infectious inflammatory brain condition in dogs, linked to abnormal autoimmune responses, and this study reviews the effects of different immunosuppressants on survival and clinical outcomes.
- A total of 82 dogs were assessed, revealing varying median survival times based on the treatment: leflunomide had the longest (1035 days), while a combination therapy showed the shortest (132 days), with no significant difference in adverse event rates except for moderate to severe anemia in one group.
- The findings suggest that the type of immunosuppressant impacts survival and response, particularly highlighting leflunomide as effective, but the study calls for
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!